If you are asking what is Semax, the short answer is that it is a synthetic peptide derived from a fragment of the adrenocorticotropic hormone (ACTH) that has been studied in laboratory and preclinical neuroscience research. Semax is most often described in the scientific literature as a synthetic ACTH(4-10) analog investigated for its effects on learning, neurotrophic signaling, and neuroprotection in animal and cell-culture models. This overview summarizes what peer-reviewed and preclinical research has examined, with an emphasis on reading the evidence critically rather than drawing conclusions the data do not support.
What Is Semax at the Molecular Level?
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Structurally, it combines the ACTH(4-7) fragment of adrenocorticotropic hormone with a C-terminal Pro-Gly-Pro tripeptide. The added proline-glycine-proline “tail” is understood in the literature to improve the molecule’s metabolic stability relative to the native hormone fragment. Importantly, Semax is described as a non-corticotropic analog, meaning that in research models it does not reproduce the classic steroidogenic (cortisol-releasing) actions of full-length ACTH while retaining behaviorally active properties studied by researchers.
A separate line of chemistry research has examined how Semax coordinates metal ions such as copper(II) and zinc(II), and how modifying the peptide’s N-terminus alters that coordination and its behavior in neuroblastoma cell lines. This work is relevant because copper and zinc dyshomeostasis is implicated in several models of neurological disease, making the peptide’s metal-binding chemistry a subject of investigation in its own right.
Origins and Research Context
Semax emerged from Russian peptide research programs, and much of the primary literature originates from institutions such as the Institute of Molecular Genetics of the Russian Academy of Sciences. Within this body of work it is frequently categorized as a “nootropic” and “neuroprotective” peptide, but those descriptors reflect the research questions investigators have posed, not established outcomes in humans. As a research compound, Semax has been used chiefly as a tool to probe melanocortin-related signaling and neurotrophic pathways in controlled laboratory settings.
Mechanisms Studied in Preclinical Models
Several mechanistic threads recur in the preclinical literature. One of the most examined is the peptide’s relationship to brain-derived neurotrophic factor (BDNF). In rats, a single intranasal application of Semax was reported to increase BDNF protein and the phosphorylation of its receptor TrkB in the hippocampus, alongside changes in a conditioned-avoidance behavioral measure. Researchers interpreted this as evidence that the peptide may modulate the hippocampal BDNF/TrkB system, though these are animal findings.
A second thread concerns monoamine neurotransmitters. In rodents, Semax was observed to influence striatal serotonergic activity and to enhance amphetamine-evoked dopamine release and locomotor activity, suggesting a modulatory rather than directly stimulatory profile in those models. A third line of in vitro work reported that Semax increased the survival of cholinergic basal forebrain neurons in culture and raised choline acetyltransferase activity, cell populations of interest because they degenerate in Alzheimer-type pathology. The authors themselves noted that the implications for disease remain to be clarified.
What the Semax Research Literature Has Investigated
Beyond mechanism, investigators have studied Semax in several disease-model contexts. In transgenic mouse models of Alzheimer-type amyloidosis, Semax and a derivative were reported to improve performance on behavioral tasks and to reduce amyloid inclusions in the cortex and hippocampus in one 2025 study. In rodent models of chronic unpredictable stress, ACTH(4-10) analogs including Semax were associated with attenuated anhedonia and preserved hippocampal BDNF, prompting researchers to describe “antidepressant-like” effects in those paradigms. Related developmental work examined whether the peptide could offset behavioral and neurochemical changes following early-life SSRI exposure in rats.
There is also a clinical research literature, largely from Russian groups, examining Semax in the setting of ischemic stroke rehabilitation, where studies reported associations between the peptide, plasma BDNF levels, and functional recovery scores. These reports should be read with attention to study size, blinding, publication language, and independent replication. The overall evidence base remains preliminary and heavily weighted toward animal and mechanistic work rather than large, replicated human trials.
Reading the Evidence Critically
Anyone evaluating Semax should note several caveats. Much of the foundational research comes from a concentrated set of laboratories, human data are limited and often not double-blind, and effect sizes in animal studies do not translate directly to people. Terms like “nootropic” and “neuroprotective” describe hypotheses under study, not proven benefits. Understanding the science before drawing conclusions is the appropriate stance: Semax is best characterized as a research peptide with an interesting but still-developing evidence profile.
References
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 2006. DOI: 10.1016/j.brainres.2006.07.108
- Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 2005. DOI: 10.1007/s11064-005-8826-8
- Grivennikov IA, et al. Effects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neurons. Restorative Neurology and Neuroscience, 2008. PubMed: 18431004
- Magrì A, et al. Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry, 2016. DOI: 10.1016/j.jinorgbio.2016.08.013
- Inozemtseva LS, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II in a model of chronic unpredictable stress. European Journal of Pharmacology, 2024. DOI: 10.1016/j.ejphar.2024.177068
- Glazova NY, et al. Semax attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 2020. DOI: 10.1016/j.npep.2020.102114
- Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova, 2018. DOI: 10.17116/jnevro20181183261-68
- Radchenko A, et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in an Animal Model of Alzheimer’s Disease. Acta Naturae, 2025. Consensus record
Citations retrieved via PubMed and Consensus. Please consult the original sources for full methodological detail.
Research-Use-Only Disclaimer: The information above is provided solely for educational and scientific purposes. Semax is described here as a research compound intended for laboratory and research use only. It is not a dietary supplement, drug, or medical product, and nothing on this page is intended to diagnose, treat, cure, or prevent any disease or to guide human or veterinary use. No content here should be interpreted as medical advice or as instructions for administration in humans or animals.